Skip to main content
eScholarship
Open Access Publications from the University of California

Development of Sézary syndrome following the administration of dupilumab

  • Author(s): Tran, Jessica
  • Morris, Lisa
  • Vu, Alan
  • Duvic, Madeleine
  • et al.
Creative Commons 'BY-NC-ND' version 4.0 license
Abstract

Dupilumab is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. It is the first biologic agent to demonstrate efficacy in treating moderate-to-severe refractory atopic dermatitis [1, 2]. Although dupilumab provides promise for the treatment of atopic and allergic conditions, clinicians should take into account its novelty and the potential for unexpected adverse events. We present a patient who developed Sézary syndrome following the initiation of dupilumab.

Main Content
Current View